E. Clark

发表

Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection.

Fei Huang, Xia Han, F. Huang, 2007, Cancer research.

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer

S. Shak, J. Baker, D. Watson, 2011, British Journal of Cancer.

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer

S. Shak, J. Baker, D. Watson, 2011, British Journal of Cancer.

Preclinical discovery and clinical validation of predictive markers of response to cetuximab (Erbitux™) in metastatic colorectal cancer

L. Ploughman, C. Langer, Xin Huang, 2006 .

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

Manuel Hidalgo, Xin Huang, Shujian Wu, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of sex on the development of melanoma in hybrid fish of the Genus Xiphophorus.

M. Siciliano, E. Clark, A. Perlmutter, 1971, Cancer research.

Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).

C. A. Roberts, A. Rabow, M. Waring, 2016, Journal of medicinal chemistry.

Evaluation of tumor gene expression and K-Ras mutations in FFPE tumor tissue as predictors of response to cetuximab in metastatic colorectal cancer

S. Shak, J. Baker, D. Watson, 2008 .

Identification of sensitivity markers for BMS-536924, an inhibitor for insulin-like growth factor-1 receptor

Xia Han, F. Huang, L. Helman, 2007 .

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

J. A. Hendricks, David M. Wilson, S. Kazmirski, 2018, Nature Communications.

Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation

Weiguo Qing, C. Reimer, C. D’Cruz, 2016, Oncotarget.

Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.

T. Yeatman, D. Coppola, P. Majumder, 2010, Cancer research.

Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring

Fei Huang, F. Huang, Li-an Xu, 2007, Genome Biology.

Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro

F. Huang, J. Hansson, M. Eskandarpour, 2009, International journal of cancer.

BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors

G. Mills, A. Dulak, Wei Zhao, 2018, PloS one.

The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.

Xia Han, F. Huang, F. Lee, 2009, Cancer research.

Rationale for Combining with EGFR / HER 2 Inhibitors Growth Factor-1 Receptor Inhibitor ( BMS-536924 ) and The Mechanisms of Differential Sensitivity to an Insulin-like Updated

Xia Han, F. Huang, F. Lee, 2008 .

Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.

T. Powles, E. Jonasch, T. Choueiri, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models

Rhys D O Jones, S. Cairo, S. Fawell, 2015, Clinical Cancer Research.

Patient Selection Sensitivity in Solid Tumors to Dasatinib : Rationale for Identification of Candidate Molecular Markers Predicting

Peter Shaw, Xia Han, F. Huang, 2007 .

Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib

O. Sansom, F. Lee, V. Brunton, 2006, Molecular Cancer Therapeutics.

Hematologic and Cytogenetic Responses in Imatinib-Resistant Chronic Phase Chronic Myeloid Leukemia Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study.

C. Sawyers, H. Kantarjian, A. DeCillis, 2004 .

Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer.

J. Baselga, E. Kubista, Li-an Xu, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Potent and selective bivalent inhibitors of BET bromodomains.

A. Dulak, A. Rabow, M. Waring, 2016, Nature chemical biology.

J. Baselga, S. Swain, X. Pivot, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

The Differential Role of Protein Kinase C Isozyme in the Rapid Induction of Neurofilament Phosphorylation by Nerve Growth Factor and Phorbol Esters in PC12 Cells

V. Lee, E. Clark, 1991, Journal of neurochemistry.

Translational Modeling of Drug‐Induced Myelosuppression and Effect of Pretreatment Myelosuppression for AZD5153, a Selective BRD4 Inhibitor

E. Clark, TA Collins, M. Mondal, 2017, CPT: pharmacometrics & systems pharmacology.

Predictive biomarker discovery and validation for the targeted chemotherapeutic ixabepilone.

J. Baselga, Shujian Wu, Li-an Xu, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ixabepilone (BMS-247550) plus trastuzumab combination chemotherapy induces synergistic antitumor efficacy in HER2 dependent breast cancers and is accompanied by modulation of molecular response markers

F. Lee, S. Castaneda, I. Inigo, 2005 .

A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant accelerated and blast phase chronic myeloid leukemia (CML): Results from CA180002

C. Sawyers, H. Kantarjian, A. DeCillis, 2005 .

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

G. Mills, A. Dulak, A. Rabow, 2016, Molecular Cancer Therapeutics.

A single-arm biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer (PRCC).

T. Powles, E. Jonasch, T. Choueiri, 2017 .

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

L. Staudt, W. Wilson, J. Vose, 2019, Blood.

Ras Activation Is Necessary for Integrin-mediated Activation of Extracellular Signal-regulated Kinase 2 and Cytosolic Phospholipase A2 but Not for Cytoskeletal Organization*

R. Hynes, E. Clark, Edwin A. Clark, 1996, The Journal of Biological Chemistry.

395 cMet: Proof-of-concept clinical trial with volitinib in patients with advanced papillary renal cell cancer (PRCC)

T. Powles, E. Jonasch, T. Choueiri, 2014 .

First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed/refractory (RR) malignant solid tumor and lymphoma: Preliminary data.

G. Fabbri, H. Edlund, K. Sachsenmeier, 2019, Journal of Clinical Oncology.

Abstract P5-18-26: Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC)

A. Schneeweiss, J. Baselga, S. Swain, 2012 .

Correlation of clinical response to BMS-354825 with BCR-ABL mutation status in imatinib-resistant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph+ ALL)

C. Sawyers, H. Kantarjian, N. Donato, 2005 .

Integrins and signal transduction pathways: the road taken.

J. Brugge, E. Clark, E. Clark, 1995, Science.

Abstract 311: AZD4320 is a potent, dual Bcl-2/xLinhibitor that rapidly induces apoptosis in preclinical hematologic tumor models

E. Hennessy, J. Secrist, E. Clark, 2018, Molecular and Cellular Biology / Genetics.

Dynamics of mammalian high‐molecular‐weight neurofilament subunit phosphorylation in cultured rat sympathetic neurons

Virginia M. Y. Lee, E. Clark, E. Clark, 1991, Journal of neuroscience research.

Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro

F. Huang, J. Hansson, M. Eskandarpour, 2009, International journal of cancer.

Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring

F. Huang, Li-an Xu, F. Lee, 2007, Genome Biology.

Abstract 3114: Targeting MET in preclinical models to support the clinical development of Volitinib in NSCLC

Weiguo Qing, C. D’Cruz, M. Frigault, 2014 .